These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An interview with Martin Rosenberg, Ph.D. Interviewed by Vicki Glaser. Rosenberg M Assay Drug Dev Technol; 2009 Dec; 7(6):537-43. PubMed ID: 20035618 [No Abstract] [Full Text] [Related]
5. Three researchers developing therapies based on RNA interference talk about their experiences leaving academia for biotech companies. Bonetta L Biotechniques; 2007 Apr; 42(4 Suppl):S10-11, S16. PubMed ID: 18798733 [No Abstract] [Full Text] [Related]
6. Profile: William Haseltine. Herrera S Nat Biotechnol; 2005 Aug; 23(8):913. PubMed ID: 16082351 [No Abstract] [Full Text] [Related]
8. Profile: Una Ryan. Schmidt C Nat Biotechnol; 2006 Aug; 24(8):881. PubMed ID: 16900115 [No Abstract] [Full Text] [Related]
9. Masters of their universe. Osborne R; DeFrancesco L Nat Biotechnol; 2009 Jun; 27(6):528-30. PubMed ID: 19513053 [TBL] [Abstract][Full Text] [Related]
10. The biopharmaceutical industry in China: history and future perspectives. Gao K; Wang J Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299 [TBL] [Abstract][Full Text] [Related]
11. Venter's departure sees Celera seek therapies. Dennis C Nature; 2002 Jan; 415(6871):461. PubMed ID: 11823816 [No Abstract] [Full Text] [Related]
12. Profile: Jean Deleage. Ratner M Nat Biotechnol; 2005 Oct; 23(10):1197. PubMed ID: 16211047 [No Abstract] [Full Text] [Related]
16. Ten years on--the European perspective. Biotech company founders talk about what made their companies tick. Collingham DP Biotechnology (N Y); 1993 Mar; 11(3):S44-6. PubMed ID: 7763435 [No Abstract] [Full Text] [Related]
17. Perspectives: biotechnology in Czech Republic, the past and the future. Damborský J; Prokop Z; Kostka M Biotechnol J; 2006 May; 1(5):487-90. PubMed ID: 16892283 [No Abstract] [Full Text] [Related]